Grant - Winter 2019 - FSHD - Davide Gabellini, PhD
"With our work, we hope to better understand how DUX4 is regulated and how we could control aberrant DUX4 in FSHD for therapeutic purposes."
Davide Gabellini, PhD, head of the Gene Expression and Muscular Dystrophy Unit at IRCCS Ospedale San Raffaele in Milan, Italy, was awarded an MDA research grant totaling $297,738 over three years to study how specific factors decrease double homeobox 4 protein (DUX4), the protein known to cause facioscapulohumeral muscular dystrophy (FSHD).
FSHD leads to progressive degeneration of muscles, with the most pronounced effects appearing in muscles of the face, shoulder blades, and upper arms. FSHD is caused by abnormal expression of DUX4, which causes toxicity and muscle cell death. Using a whole-genome approach, Dr. Gabellini previously identified one factor as an inhibitor of DUX4. This protein directly binds to DUX4, blocking its ability to activate certain genes that eventually cause cell death.
In this study, Dr. Gabellini aims to clarify the DUX4 biological pathway and the mechanism by which DUX4 causes cell death. Specifically, he will identify the minimal binding domain needed for the identified factor to inhibit DUX4 and determine if its overexpression can prevent FSHD mice and patient cells from dying. Interestingly, mutations in this protein’s gene are associated with familial amyotrophic lateral sclerosis (ALS), so Dr. Gabellini will also assess the impact of specific mutations found in ALS on their ability to inhibit DUX4.
Grantee: FSHD - Davide Gabellini, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Winter 2019 - ALS - Csaba Konrad, PhD
"We believe finding biomarkers that stratify sporadic ALS patients into subgroups with shared cellular pathology may be the key to improving clinical trial design."
Csaba Konrad, PhD, postdoctoral associate in Neuroscience at Weill Cornell Medical College, was awarded an MDA development grant totaling $210,000 over three years to utilize a large bank of skin cells derived from sporadic amyotrophic lateral sclerosis (ALS) patients to determine if the cells can be clustered into groups based on changes in size and shape. He hopes to use these models to improve ALS patient stratification in clinical trials.
Developing drugs to treat ALS has proven difficult as there are many causes of the disease, resulting in a highly diverse patient population and a dearth of biomarkers. Biomarkers can be used for predicting disease progression and response to therapy, for early detection and accurate diagnosis, and for patient stratification in clinical trials — making biomarker discovery for ALS of high priority.
In previous work, Dr. Konrad showed that skin fibroblast cells are affected by the some of the same pathological changes as motor neurons. In this work, he will use his large bank of ALS patient-derived skin fibroblast cell lines to study differences in morphological features of these cells under stress. By using machine learning techniques, he will build models based on patterns of features that can be used to distinguish between healthy and ALS cells, models to predict clinical characteristics of the disease, and models to define subgroups of ALS patient cells that share similar abnormal features and cellular pathology.
https://doi.org/10.55762/pc.gr.84538
Grantee: ALS - Csaba Konrad, PhD
Grant type: Development Grant
Award total:
Institution:
Country:
Grant - Winter 2019 - CMT - Charles Abrams, MD, PhD
"Unraveling the cause of a human disease requires having appropriate animal models for the disease being studied. This proposal will characterize models for CMT1X on the molecular level and use them to initiate studies that will shed light on the causes of this disorder."
Charles Abrams, MD, PhD, professor of Neurology at the University of Illinois, Chicago, was awarded an MDA research grant totaling $300,000 over three years to better understand how mutations in the connexin 32 gene (Cx32) lead to CMT1X, a form of Charcot-Marie-Tooth disease (CMT).
Mutations in the gene coding for the gap junction beta-1 protein (GJB1), also known as connexin 32 protein (Cx32), are associated with the X-linked form of Charcot-Marie-Tooth disease (CMT1X), which affects approximately 1 in 25,000 people and is the second-most-common form of CMT. Although scientists have known about these mutations for more than 25 years, information is still lacking about how they cause disease. In the case of CMT1X, animal models are inadequate — almost all studies have used the Cx32 gene knockout mouse, a loss-of-function model that may not accurately represent the full spectrum of the variety of mutations in Cx32 that can cause CMT1X.
This work will use a technique called RNA-Seq to characterize a variety of different CMT1X mouse models at the level of transcription (RNA), and it will then utilize this information for studies into the causes of this disease. Dr. Abrams will use these different knockout and mutant models to determine how gene expression in Schwann cells is affected by mutations, and how this change in gene expression leads to axonal death. Schwann cells are very important in that they generate the insulating myelin sheath around peripheral nerves. If successful, the project could provide insights into how genetic defects in supportive Schwann cells cause degeneration of the axons in CMT as well as identify which CMT1X patients may benefit from gene-replacement therapies under development.
https://doi.org/10.55762/pc.gr.84541
Grantee: CMT - Charles Abrams, MD, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Winter 2019 - DMD - Chad Heatwole, MD
"At the completion of our work the DMD research community will have multiple validated outcome measures to aid in therapeutic assessment and encourage therapeutic development for DMD."
Chad Heatwole, MD, associate professor of Neurology at the University of Rochester Medical Center in N.Y., was awarded an MDA Human Clinical Trial Grant totaling $200,000 over two years to develop and validate a health index to be used as a patient-reported outcome (PRO) tool in clinical trials for Duchenne muscular dystrophy (DMD).
While the plethora of varied symptoms of DMD are well known to patients and their doctors, the prevalence and relative importance of the collective set of symptoms has never been found in a large study of DMD patients. The DMD research community lacks a PRO that satisfies all stakeholder groups and is in standard use. The FDA has clearly expressed a desire for such data, so it is critical that the field arrive at a consensus around a validated tool. Dr. Heatwole has previously developed and validated more than 30 disease-specific instruments currently being used in academic and government organizations and pharmaceutical companies around the world.
In this work, Dr. Heatwole will develop and validate PRO measures for DMD clinical trials. He will use patient interviews and a large cross-sectional study to identify the symptoms that are most important to DMD patients. Next, he will develop patient-centered, disease-specific outcome measures for DMD clinical trials using FDA guidelines, to be known as the DMD Health Indices. Finally, he will optimize DMD Health Indices using patient interviews and group testing, among others.
https://doi.org/10.55762/pc.gr.83904
Grantee: DMD - Chad Heatwole, MD
Grant type: Human Clinical Trial Grant
Award total:
Institution:
Country:
Grant - Winter 2019 - Congenital & Other Myopathies – Alan Beggs, PhD
Alan Beggs, PhD, professor of Pediatrics at Harvard Medical School and director of the Manton Center for Orphan Disease Research at Children’s Hospital Boston, has been awarded an MDA research grant totaling $300,000 over three years to continue his previous research on the molecular genetics of congenital myopathies.
Congenital myopathies are a diverse group of inherited neuromuscular conditions caused by defects in skeletal muscle and include central core disease (CCD) and other core myopathies, nemaline myopathy, myotubular myopathy (MTM) and other centronuclear myopathies (CNMs), congenital myopathies with fiber-type disproportion (CFTDs), and others (some of these have not yet been identified). In previous MDA-funded work, Dr. Beggs built an extensive data registry and repository of samples from patients and their families. His screening for congenital myopathy-causing mutations in zebrafish led to the discovery of mutations in several genes that may be related to human neuromuscular diseases. His further analyses determined the nature of these mutations, their relationships to the muscle defects seen in zebrafish, and their relationships to the same genes in humans with analogous muscle findings.
In this new project, Dr. Beggs will use whole genome sequencing methods to discover the disease genes and genetic mutations that cause congenital myopathy in patients and families where the underlying cause has not yet been identified. Then, to better understand the biological pathways that lead to disease and search for effective therapies, Dr. Beggs will develop animal models with these mutations, which he will be able to use in validation studies (to test if the mutation actually causes the disease) and screening assays (to test small molecule libraries to identify new drugs to treat these conditions).
https://doi.org/10.55762/pc.gr.84542
Grantee: Congenital & Other Myopathies – Alan Beggs, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Winter 2019 - Distal Myopathy - Aikaterini Kontrogianni-Konstantopoulos, PhD
“Although mutations in MyBP-C1 have been previously linked to severe and lethal forms of distal arthrogryposis, prior to our studies there was no evidence for causal association of MyBP-C1 mutations to myopathy. Continuing funding research in this area will therefore identify additional myopathic genes that have been potentially overlooked and accurately identify new forms of myopathies.”
Aikaterini Kontrogianni-Konstantopoulos, PhD, professor of Biochemistry and Molecular Biology at the University of Maryland School of Medicine, was awarded an MDA research grant totaling $300,000 over three years to investigate a novel form of myopathy associated with mutations in the myosin binding protein-C1 gene (MyBP-C1) using in vitro (in a petri dish) experiments and mice models.
Myosin binding protein-C is part of a family of proteins that regulates muscles’ ability to contract. Mutations in the genes for the cardiac and slow skeletal isoforms have been found to cause cardiac and neuromuscular disease. MyBP-C1 codes for myosin-binding protein C, slow-type, which is expressed in slow skeletal muscle and has very recently been shown to be associated with a new form of early-onset myopathy with muscle weakness, body deformities, and tremor.
Using well-developed in vitro experiments and a preclinical animal model carrying the mutation, Dr. Kontrogianni-Konstantopoulos hopes to determine what impact this mutation has on the biochemical and biophysical properties of MyBP-C1 protein and the molecular and cellular alterations underlying the development of this novel myopathy.
https://doi.org/10.55762/pc.gr.84553
Grantee: Distal Myopathy - Aikaterini Kontrogianni-Konstantopoulos, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - Myotonic Dystrophy – Eric Wang, PhD
“We are living in an extremely exciting time because of the explosion of technological and conceptual advances, both in the context of basic science as well as therapeutic development. Technologies such as high throughput sequencing, antisense oligonucleotides, gene therapy, and small molecule targeting of RNA are transforming the NMD landscape. Several drugs have been recently approved for NMDs and will undoubtedly pave the way for treatments for other NMDs.”
Eric Wang, assistant professor of Molecular Genetics & Microbiology at the University of Florida’s College of Medicine in Gainesville, was awarded an MDA Research Grant totaling $300,000 over 3 years to study the mechanisms of central nervous system (CNS) dysfunction in myotonic dystrophy.
Myotonic dystrophy is a neuromuscular disease with significant muscle, cardiac, and CNS symptoms. A significant amount of research on the skeletal muscle aspects of the disease has enabled clinical trials aimed at addressing muscle symptoms. CNS features of the disease can also be extremely debilitating, but the molecular basis is poorly understood. Building a solid foundation to understand molecular pathogenesis in the CNS, along with developing new animal models and therapeutics, are high priorities for this disease.
Dr. Wang and colleagues plan to identify RNA changes in mouse models of DM1, as well as from postmortem brains from DM1 individuals. The team will pattern its efforts after previous successes in identifying drivers of disease in muscle cells.
These studies will pave the way for future therapeutic development by identifying genes and pathways that are perturbed in the DM1 CNS, as well as by defining biomarkers that can be used to monitor therapeutic rescue in response to candidate therapies.
Grantee: Myotonic Dystrophy – Eric Wang, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - ALS – Ludo Van Den Bosch, PhD
“Amyotrophic lateral sclerosis (ALS) is a terrible disease, and despite all the research done in the past, patients still die (usually very fast). With our research, we want to contribute to the development of a cure! The proposed strategy can be translated relatively fast into a new therapy as the class of drugs that we are testing have already been tested in patients suffering from other diseases (e.g. cancer).”
Ludo Van Den Bosch, principal investigator at VIB in Leuven, Belgium, was awarded an MDA Research Grant totaling $300,000 over 3 years to study the role of histone deacetylase inhibitors in amyotrophic lateral sclerosis (ALS).
ALS is a neurodegenerative disease caused by the progressive failure of the motor system. Success in clinical translation of treatments for ALS has been poor and patients urgently need new therapeutic approaches.
Both in ALS patients and in mouse models of ALS, the motor axon is the most vulnerable compartment determining weakness and survival of the nerve cell. Histone deacetylase 6 (HDAC6) plays an important role in the regulation of axonal transport. Inhibition of HDAC6 can reverse the axonal transport deficits induced by mutant proteins. Previous work from the Van Den Bosch lab showed that inhibition of HDAC6 has a positive effect on mouse models of Charcot-Marie-Tooth disease (CMT), most likely due to reinnervation of the neuromuscular junctions.
Dr. Van Den Bosch and colleagues plan to inhibit HDAC6 in mouse models of ALS and to investigate the underlying mechanism of potential positive effects. Overall, the aim of this project is to find positive preclinical evidence for the use of HDAC inhibitors to treat ALS.
Grantee: ALS – Ludo Van Den Bosch, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - CMT – Vincent Timmerman, PhD
“If we can successfully validate our research hypothesis, reducing the expression of HSPB8 in vivo and decreasing the detrimental effects of the mutant protein, we may have found the first-ever treatment for dHMN patients having HSPB8 mutations. To reach this objective, we will focus on already-approved compounds and anti-sense oligonucleotides (ASOs).”
Vincent Timmerman, group leader at the University of Antwerp in Belgium, was awarded an MDA Research Grant totaling $300,000 over 3 years to study neuromuscular disease caused by HSPB8 mutations.
Patients with distal hereditary motor neuropathy, a variant of Charcot-Marie-Tooth neuropathy, have a progressive degeneration of their peripheral nerves resulting in muscle weakness and atrophy. Dr. Timmerman and colleagues were the first to report disease-causing mutations in the HSPB8 gene. The small heat shock protein B8 (HSPB8) belongs to the “stress protein family” and is expressed in various tissues and cells. HSPB8 acts as a molecular chaperone by clearing protein aggregates and reducing their toxic accumulation. This protective function has been studied in the context of cancer and neurodegenerative disease.
Building on the discovery, Dr. Timmerman’s team generated a mouse model mimicking the disease by introducing a mutation in the Hspb8 gene (a “knock-in” mouse). In addition, the team also made a model in which they deleted Hspb8 (a “knock-out” mouse), and these animals developed a mild myopathy.
The next step aims to identify therapeutic compounds that can rescue or delay the neurodegeneration observed in the knock-in model, or that can result in a milder phenotype as seen in the knock-out animals. The identified small-molecule compound acting on the expression of HSPB8 could be beneficial to treat patients affected with distal hereditary motor neuropathy and also patients with distal myopathies and related neuromuscular disorders.
Grantee: CMT – Vincent Timmerman, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - FSHD – Francis Michael Sverdrup, PhD
“I was inspired to start drug discovery research in FSHD when my daughter was diagnosed with the disease at the age of 10. Because no treatments are currently available, I have a strong motivation to help the field advance promising drug targets into clinical trials. With clinical trials for FSHD on the horizon, it is very exciting to see the rewards of the hard work by many talented scientists over the last 20 years. It is no longer just about the basic research but moving this knowledge to treatments.”
Francis Michael Sverdrup, associate professor of Biochemistry and Molecular Biology at Saint Louis University in Missouri, was awarded an MDA Research Grant totaling $300,000 over 3 years to study drugs targeting DUX4 expression in facioscapulohumeral muscular dystrophy (FSHD).
DUX4 protein produced in skeletal muscle is considered to be the key cause of muscle degeneration in FSHD. Therefore, suppressing DUX4 expression is a primary therapeutic approach for halting disease progression. Identifying drug candidates for this purpose is a critical step. Such drugs would prevent the many detrimental activities of this toxic protein and potentially provide the first candidate therapies for slowing or stopping disease progression in FSHD.
Dr. Sverdrup and colleagues recently identified 2 classes of drugs that suppress DUX4 using cell-based screens. Additionally, they have identified a class of modulators of intracellular signaling that similarly decrease DUX4 expression in differentiating FSHD muscle cells. Comparison of these 3 drug classes and understanding the mechanisms of DUX4 repression for each is a critical step in advancing the best therapy toward the clinic.
The proposed experiments will show which drugs are best at controlling DUX4 expression in animal muscles and therefore will be best suited for advancing to human clinical trials.
Grantee: FSHD – Francis Michael Sverdrup, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - DMD – Melissa Spencer, PhD
“One of the biggest barriers to success for gene therapies is the ability to deliver the cargo to the tissue of interest. In our case, the goal is to reframe the DMD gene in skeletal muscle and the heart. By developing a systemically injectable nanoparticle delivery platform, we hope to have a mechanism to use to deliver our CRISPR platform to multiple muscles in the body.”
Melissa Spencer, professor of Neurology at the University of California at Los Angeles, was awarded an MDA Research Grant totaling $300,000 over 3 years to work on the development of nanoparticles for the treatment of neuromuscular disorders.
For Duchenne muscular dystrophy (DMD), a primary goal of therapy development is to correct the DMD gene mutation. To that end, researchers are developing therapies such as micro-dystrophin (a smaller version of dystrophin) gene replacement and CRISPR Cas9 gene editing. In each case, they are relying on a small virus called AAV (adeno-associated virus) to deliver these therapies to the muscles and heart within the body.
However, AAV-based delivery of these therapies poses a couple of ongoing challenges. The first challenge with AAV-based delivery is that it is not completely efficient at targeting muscle cells and may target other cells. The second challenge is that AAV is a virus that exists in the environment. This means that some people may have already been exposed to AAV and could reject the AAV when it’s given as a therapy. Also, because of this immune response, AAV can be administered only one time to a person, which could be a problem if re-dosing is necessary.
To address these issues with the AAV-based approach, the Spencer lab is developing nanoparticles as an alternative method for delivering gene-editing and gene-replacement therapies. Nanoparticles are very small (1 nanometer) organic or inorganic molecules that can carry drugs or nucleic acids (DNA or RNA) and can be re-administered multiple times. Additionally, the nanoparticles are transient, so if unwanted side effects or safety concerns occur, nanoparticle administration could be discontinued. Using this approach, the investigators hope to develop a better delivery vehicle for systemically injected gene-replacement and gene-editing therapies to muscle.
Grantee: DMD – Melissa Spencer, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - LGMD – Dorianna Sandona, PhD
“In the last years, researchers understood that to fight orphan diseases the sole possibility is to join forces and share data. I think that people with NMDs must have hope in research. The way to identify an effective therapy is long and full of hurdles. We don’t want to create false hope; however, we are doing our best, and we need patients’ enthusiasm and support.”
Dorianna Sandona, research scientist at the University of Padova in Italy, was awarded an MDA Research Grant totaling $300,000 over 3 years to study novel zebrafish models of sarcoglycanopathy subtypes of limb-girdle muscular dystrophy.
The sarcoglycanopathies are a subtype of LGMD caused by defects in alpha-, beta-, gamma-, and delta-sarcoglycans (SGs). SGs are components of an essential complex for muscle integrity, as they help stabilize the muscle membrane during muscle contractions.
In order to screen for molecules able to restore a functional SG-complex, Dr. Sandona will mimic sarcoglycanopathy in zebrafish and develop an advanced in vitro model based on cells derived from patients. Both models will be utilized to assess efficacy and safety of the small molecules for use as potential therapeutics. Zebrafish are a versatile model organism that allows for simple functional assays to test any potential drug. On the other hand, the model based on patient’s cells allows researchers to evaluate the efficacy of compounds directly on human, pathologic samples. If successful, the work, combining data coming from the different models, may shorten the gap toward therapy testing in this class of LGMD.
https://doi.org/10.55762/pc.gr.81540
Grantee: LGMD – Dorianna Sandona, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - ALS – Jeffrey D. Rothstein, MD, PhD
“Answer ALS is a nationwide consortium that is assembling the largest and most comprehensive ALS dataset to date, in which clinical, behavioral, and extensive cellular datasets will be collected from 1000 patients.”
Jeffrey D. Rothstein, director of the Brain Science Institute and director of the Robert Packard Center for ALS Research at Johns Hopkins University School of Medicine in Baltimore, Maryland, was awarded an MDA grant totaling $550,000 over 3 years for Answer ALS, a tool for data integration and characterization of disease networks.
Amyotrophic lateral sclerosis (ALS) is a progressive disease of the nerve cells that leads to loss of voluntary muscle control, paralysis, difficulty speaking, swallowing, and, ultimately, breathing. Today, scientists recognize that ALS is unlikely to be one disease; rather, it may be a collection of subtypes and variants, each of which requires a different approach for optimal treatment.
Answer ALS is a nationwide consortium that is assembling the largest and most comprehensive ALS dataset to date, in which clinical, behavioral, and extensive cellular datasets will be collected from 1000 patients. This comprehensive dataset will allow, for the first time, in-depth study of the underlying disease mechanisms. Mining this rich, complex dataset with the goal of identifying ALS disease subtypes requires sophisticated computational tools.
The support for this project will facilitate the development of a series of these tools, known as probabilistic graphical models (PGMs), to specifically interrogate and interpret the combined Answer ALS datasets. PGMs have been used extensively in applications from finance to artificial intelligence and health care diagnostics. These flexible, interpretable models are able to identify and quantify changes in cellular pathways. Creation and application of PGMs to enable integrated models of this comprehensive dataset will enhance our understanding of disease mechanisms and advance the discovery of targets for effective therapy.
Grantee: ALS – Jeffrey D. Rothstein, MD, PhD
Grant type:
Award total:
Institution:
Country:
Grant - Summer 2018 - DMD – Dr. Russell Rogers, PhD
“Many cutting-edge approaches to treating DMD are currently under development. Each offers distinct advantages over current standard care. It is without a doubt that the most hope would be placed into therapies that offer the most benefit (both therapeutically and in applicability) and are on the verge of clinical translation.”
Dr. Russell Rogers, postdoctoral research fellow at Cedars-Sinai in Los Angeles, California, was awarded an MDA Development Grant totaling $120,000 over 2 years to study cell-free therapy to treat Duchenne muscular dystrophy (DMD).
In DMD, skeletal and heart muscle are highly fragile and degenerate easily, leading to loss of independence and heart disease. There are currently limited treatment options available to address the disease.
Cardiosphere-derived cells (CDCs) are cardiac progenitor cells that have been tested in preclinical and clinical studies in DMD. These studies suggest CDCs may someday be a safe and effective therapy. CDCs work by secreting nanosized particles that carry genetic information called exosomes (CDC-exos). A single dose of CDC-exos dramatically improved skeletal muscle and heart function in a preclinical animal model of DMD.
Dr. Rogers and colleagues plan to study whether CDC-exos could be beneficial in preventing the disease’s onset or delaying disease progression. The work proposed tests this hypothesis by treating DMD mice models with CDC-exos prior to significant skeletal muscle and heart disease. If the hypothesis is supported, the proposed work would be an important leap toward developing new therapeutic approaches to this refractory, progressive disease.
Grantee: DMD – Dr. Russell Rogers, PhD
Grant type: Development Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - SBMA – Carlo Rinaldi, MD, PhD
“Better understanding of the underlying disease mechanisms, coupled with improvement of gene vector design, therapeutic gene selection, and methods of delivery, have made gene therapy a realistic option for neuromuscular conditions — and neurological diseases in general — for which no treatment option was available until few years ago. Many challenges still lie ahead, but we have good reasons to be very optimistic for the future.”
Carlo Rinaldi, associate professor and clinician scientist at the University of Oxford in England, was awarded an MDA Development Grant totaling $120,000 over 3 years to study the role of androgen receptor isoforms in SBMA pathogenesis and the potential as therapeutic targets. This grant is co-funded by the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM).
Mutations in the gene encoding the androgen receptor (AR) protein cause spinal and bulbar muscular atrophy (SBMA). SBMA is an adult-onset neuromuscular condition affecting males with unmet clinical need. It is not undestood how mutations in AR lead to primary degeneration of motor neurons and muscle in patients. The activity of AR and other hormone receptors can be modulated in human cells by isoforms and/or splice variants, which may block or enhance their functions.
Dr. Rinaldi and colleagues plan to investigate the role of AR alternative isoforms in mediating SBMA toxicity. By revealing how these isoforms regulate AR activity in health and disease, researchers expect to better understand the mechanisms of disease in SBMA and provide a novel rational therapeutic target. If successful, the work could pinpoint tissue-specific targets for therapy development, with implications not only for SBMA but for other diseases of the motor unit as well, including spinal muscular atrophy and amyotrophoic lateral sclerosis.
https://doi.org/10.55762/pc.gr.81520
Grantee: SBMA – Carlo Rinaldi, MD, PhD
Grant type: Development Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - ALS – Joel Richter, PhD
“There are two outcomes we hope for. One outcome is basic understanding of how toxic peptides are generated from C9orf72. The second outcome – which is some distance in the future – will be to use our knowledge to inhibit the product ion of these toxic peptides and thereby mitigate or delay at least this one form of ALS.”
Joel Richter, Arthur F. Koskinas Chair in Neuroscience, and Fen-Biao Gao, Governor Paul Cellucci Chair in Neuroscience Research, both at the University of Massachusetts Medical School in Worcester, were awarded an MDA Research Grant totaling $300,000 over 3 years to study a potential inhibition of translation of G4C2-containing RNA as a novel therapy for C9orf72-ALS.
Amyotrophic lateral sclerosis (ALS) is a fatal disease caused by motor neuron degeneration and resulting muscle wasting. Most causes of ALS are unknown, but the most commonly known genetic cause is an aberrant C9orf72 gene expansion that leads to the toxic accumulation of dipeptide repeat proteins (DPRs).
Previous collaborative work in Drs. Richter and Gao’s labs has identified regions in C9orf72 RNA that could be blocked by binding to complementary DNA antisense oligonucleotides (AS-ODNs). Such AS-ODNs would inhibit DPR production, thereby slowing or inhibiting disease progression.
Drs. Richter and Gao propose to use human disease neurons in culture and C9orf72 model mice to test the efficacy and specificity of AS-ODNs to inhibit DPR synthesis and mitigate ALS pathophysiology. It’s hoped this work will have a major impact on the clinical treatment of ALS.
Grantee: ALS – Joel Richter, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - ALS – Laura P.W. Ranum, PhD
“We are at an exciting time in the field of repeat expansion disorders because as a research community we are starting to understand there are common threads between these diverse disorders. The field is also progressing faster and faster toward clinical trials and a growing appreciation for how therapies for one disorder may lead to similar therapies for another disorder.”
Laura P.W. Ranum, professor of Molecular Genetics and Microbiology and director of the Center for NeuroGenetics at the University of Florida’s College of Medicine in Gainesville, was awarded an MDA Research Grant totaling $300,000 over 3 years to study the contributions of RAN proteins to C9orf72 ALS/FTD.
Expansion of a section of repetitive DNA in the C9orf72 gene is the most common genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This discovery linked C9-ALS/FTD to a larger group of more than 30 different repeat expansion mutations that also cause neurodegenerative diseases. These repeat expansions are also capable of producing novel toxic proteins in the absence of the regular starting sequences. These proteins have been found in human autopsy tissue of patients with C9-ALS/FTD and other repeat-associated diseases.
Understanding how these proteins contribute to C9-ALS/FTD will be important to developing effective treatment strategies. Dr. Ranum and colleagues have generated mice that successfully mimic the disease features of ALS/FTD patients and will use these mice to understand how the body reacts to these novel proteins and if this interaction contributes to disease. The researchers will also determine how certain cellular conditions lead to the production of these novel proteins and if these pathways can be manipulated to reduce the number of proteins produced.
These studies will result in a greater understanding of how the response to these proteins contributes to disease while also determining if scientists can modify this response to help combat this devastating disease.
Grantee: ALS – Laura P.W. Ranum, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - MG – Kevin C. O’Connor, PhD
“Overall, this work will further our understanding of how MG initiates and progresses, and uncover fundamental disease mechanisms that have the potential to change the understanding of the immunopathology. In addition, we expect to develop clinically relevant disease models that will directly impact patient care.”
Kevin C. O’Connor, associate professor of Neurology at Yale University in New Haven, Connecticut, was awarded an MDA Research Grant totaling $300,000 over 3 years to study novel isolation and investigation of pathogenic cells in myasthenia gravis (MG).
Autoimmunity is a malfunction of the immune system where an immune response develops against one’s own tissues (self). MG is an autoimmune disease caused by circulating autoantibodies (antibodies against self), produced by a malfunctioning immune system, that interrupt signaling at the neuromuscular junction. Patients experience muscle weakness, which can be deadly when muscles involved in respiration are affected.
The human immune system is comprised of trillions of cells distributed throughout the body. Only a tiny fraction directly contributes to autoimmune disease. In MG, those that contribute are a subset of B cells, which produce the autoantibodies. In order to investigate this small subset and find ways to target it, researchers need a way to isolate these autoreactive B cells from other immune cells. This advance has yet to be achieved because the technology has not been established.
To this end, Dr. O’Connor’s team has developed a novel approach for isolating the specific B cells that cause MG. The team will investigate these cells to determine how they produce disease-causing autoantibodies and how they behave during treatment and disease exacerbation. Overall, this work will further the understanding of how MG initiates and progresses, and support the application and development of therapeutics that both repair dysfunction and specifically target disease-causing cells.
Grantee: MG – Kevin C. O’Connor, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - ALS – Katharine Nicholson, MD
“By studying a population at risk for developing ALS, this project has the potential to further our understanding of underlying early disease mechanisms to allow for the development of novel therapeutics that target the earliest changes in ALS.”
Katharine Nicholson, instructor and assistant in Neurology at Massachusetts General Hospital in Boston, was awarded an MDA Clinical Training Research Scholarship totaling $86,666 over 2 years to study early markers of disease in C9orf72 ALS. This grant is being co-funded by the American Brain Foundation and originated as part of a partnership with the ALS Association.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting primarily the motor neurons and causing weakness. Familial ALS accounts for about 10% of all ALS and is most commonly caused by the C9orf72 (C9) repeat expansion. With advances in our understanding of genetically mediated ALS, there are many asymptomatic individuals in families known to harbor ALS genes who are motivated to participate in research.
The identification of early ALS could assist with better recognition, faster referral of possible cases, and more timely diagnosis for earlier treatment and improved outcomes for people with ALS. Delays in diagnosis postpone ALS patient access to multidisciplinary care, initiation of disease-modifying drugs, and participation in clinical trials. Researchers are unable to target people in the early stages the disease, impeding early enrollment in therapeutic trials before substantial neurodegeneration has occurred. Thus, uncovering the earliest biological and clinical changes in ALS has the potential to have an enormous impact on clinical care and dug development.
In this proposal, Dr. Nicholson and colleagues will leverage the Dominant Inherited ALS (DIALS) Network to conduct responsible genetic testing for asymptomatic people at risk of carrying the C9 gene and to study these volunteers over time to understand the biological events at play prior to the symptomatic horizon and at the time of symptom conversion. The overall goal of this project is to identify the earliest biological and clinical changes in C9-related ALS to ultimately promote early diagnosis, novel target identification for drug trials, and eventual pre-symptomatic treatment trials.
Grantee: ALS – Katharine Nicholson, MD
Grant type: Clinical Research Training Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - CMD & Congenital Myopathies – Francesco Muntoni, MD
“Research focused on identification of the genetic basis of other neuromuscular disorders has paved the road toward development of novel therapeutic options and/or prevention strategies. We would now apply this knowledge also to the residual CMD and CMY conditions without a genetic diagnosis.”
Francesco Muntoni, chair of Pediatric Neurology in the ICH Developmental Neurosciences Programme at the UCL GOS Institute of Child Health in London, England, was awarded an MDA Research Grant totaling $300,000 over 3 years to study novel congenital muscular dystrophy (CMD) and congenital myopathy (CMY) genes.
CMD and CMY are groups of disorders that are typically present from birth. However, in approximately 50% of all CMD/CMY cases, the genetic defect that causes the disease is not known, and it is predicted that dozens of genes responsible for CMDs or CMYs are yet to be discovered. The lack of a genetic diagnosis affects patient care by limiting a clinician’s knowledge about disease progression, disease-specific complications, and heritability of the disease. In addition, these individuals are unable to participate in clinical trials as almost always a genetic diagnosis at time of enrollment is required.
Dr. Muntoni and colleagues plan to use more advanced genetic techniques to try to identify the gene-causing mutations in these unsolved CMD and CMY cases, and gain knowledge of the function of the novel disease-causing genes. It is anticipated that the findings of this project will result in significant improvements in CMD/CMY genetic diagnosis, both in trial-enrolled families and in other affected families worldwide who share involvement of the same novel genes. It will also translate to a greater understanding of the biological pathways that lead to CMDs and CMYs and, in turn, will facilitate the development of future therapies.
https://doi.org/10.55762/pc.gr.81525
Grantee: CMD & Congenital Myopathies – Francesco Muntoni, MD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - DMD – Pura Muñoz-Canoves, PhD
“New emerging advances in basic and applied science may open definitive doors to cures.”
Pura Munoz-Canoves, ICREA senior research professor at the Universitat Pompeu Fabra in Barcelona, Spain, was awarded an MDA Research Grant totaling $300,000 over 3 years to study cellular senescence, a target for combating Duchenne muscular dystrophy (DMD).
Regenerative functions of skeletal muscle stem cells (satellite cells) decline during DMD, but the mechanism is not well understood. A better understanding of this pathway will facilitate finding new alternatives to improve the regenerative capacity of the musculature in DMD patients, especially at advanced stages when regeneration is severely reduced.
Dr. Munoz-Canoves and colleagues hope to improve regeneration of DMD muscle by bringing back satellite cells to their functional state and by eliminating the dysfunctional cells. Anti-aging therapies with new pharmaceuticals willl hopefully improve regeneration of DMD muscle, which shares some features with aged muscle, concerning the regenerative decline.
Grantee: DMD – Pura Muñoz-Canoves, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - Mitochondrial Myopathies – Carlos T. Moraes, PhD
“There are no treatments for mitochondrial diseases. The unique genetics of mitochondria offer some opportunities for genetic manipulation that could be curative. Our approach has the potential to be curative. The main limitation will be delivery systems for the DNA editing enzyme, which are being developed at a fast pace.”
Carlos T. Moraes, professor of Neurology at the University of Miami’s Miller School of Medicine in Florida, was awarded an MDA Research Grant totaling $300,000 over 3 years to study monomeric gene-editing enzymes to treat mitochondrial myopathies.
Mitochondrial diseases caused by mutations in the mitochondrial DNA (mtDNA) are most often heteroplasmic, meaning that the normal mtDNA coexists with the mutant mtDNA. Disease is manifested when the cells/tissue have a very high percentage of mutant mtDNA. There are no treatments for mitochondrial diseases, but the unique genetics of mitochondria offer some opportunities for genetic manipulation that could be curative.
With previous MDA funding, Dr. Moraes and colleagues have developed approaches to reduce the percentage of mutant mtDNA using DNA-editing enzymes, but the feasibility of this approach is limited because these enzymes are difficult to deliver to affected tissues. Therefore, he has developed an innovative approach to improve the delivery of gene-editing components to mitochondria, and in this project will test the success in different animal models, improving the chances of bringing this approach to the clinics.
https://doi.org/10.55762/pc.gr.81530
Grantee: Mitochondrial Myopathies – Carlos T. Moraes, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - SMA – Jacqueline Montes, PT, EdD, NCS
Jacqueline Montes, assistant professor of Rehabilitation and Regenerative Medicine in the Program for Physical Therapy at Columbia University Medical Center in New York, New York, was awarded an MDA clinical trial travel grant totaling $60,000 to help support the costs of patients traveling to participate in a trial to study oxidative capacity and exercise tolerance in ambulatory SMA.
In a previous study, Dr. Montes’ team found that exercise does not improve function or fitness in ambulatory SMA children and adults despite increases in exercise ability. Understanding the underlying mechanisms preventing the expected improvements is necessary to design appropriate treatment strategies for SMA patients to benefit from exercise.
There has been laboratory evidence to suggest that mitochondria are affected by lack of SMN. A reduction in oxidative capacity disproportionate to lean mass and disease severity would further support evidence of mitochondrial depletion in SMA. Alternative exercise training strategies and/or concomitant targeted therapeutic intervention may be necessary to achieve an aerobic conditioning effect.
The results from this 6-month observational study of 42 patients (14 ambulatory SMA, 14 ambulatory mitochondrial myopathy, and 14 healthy controls) would provide preliminary data, using non-invasive methods, on oxidative capacity in ambulatory SMA patients and disease controls to aid in the design of exercise intervention studies. Furthermore, this information would link previous laboratory and preclinical findings of mitochondrial depletion in SMA to the clinical condition and provide important information for future studies designed to improve oxidative capacity and fitness in SMA patients.
https://doi.org/10.55762/pc.gr.80672
Grantee: SMA – Jacqueline Montes, PT, EdD, NCS
Grant type:
Award total:
Institution:
Country:
Grant - Summer 2018 - ALS – Danilo Medinas, PhD
Danilo Medinas, staff scientist at the Instituto de Neurociencia Biomedica in Santiago, Chile, was awarded an MDA Research Grant totaling $240,000 over 3 years to study the potential of targeting ERp57 to treat amyotrophic lateral sclerosis (ALS).
ALS is a deadly motor neuron disease characterized by muscle weakness, paralysis, and premature death. The primary mechanism responsible for the loss of motor neurons remains unknown. The failure of protein quality control in a subcellular “protein factory” called endoplasmic reticulum (ER) has been identified as a common factor driving motor neuron degeneration.
Previous studies from the Medinas lab identified mutant genes in ALS patients that produce dysfunctional mutant proteins in the ER and adversely impact motor neuron connectivity to muscles. Interestingly, the levels of this family of proteins residing in the ER increase in ALS patients carrying mutations in other genes, meaning the mechanisms are similar in distinct ALS cases. Dysfunction of these ER-resident proteins may underlie early pathogenic events of ALS by impairing the communication between motor neurons and muscles.
To investigate this hypothesis, Dr. Medinas and colleagues engineered mice to produce the mutant proteins found in ALS patients for disease modeling. In addition, they will test a gene therapy strategy designed to boost production of functional proteins in the ER and restore motor neuron activity. The research approach aims to uncover common pathological mechanisms of ALS and validate novel therapeutics to recover motor neurons.
https://doi.org/10.55762/pc.gr.81521
Grantee: ALS – Danilo Medinas, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
Grant - Summer 2018 - ALS – Christopher McDermott, MBChB, FRCP, PhD
“There have been conflicting studies with regards to whether diaphragm pacing is a good thing to offer people living with ALS to support their breathing. This study is about making sure patients do not receive an intervention that may potentially do more harm than good.”
Christopher McDermott, professor of Translational Neurology at the University of Sheffield in England, was awarded a research grant totaling $60,000 over 9 months to create a task force to provide unbiased analysis of diaphragm-pacing studies in ALS. This grant is co-funded by MDA, the ALS Association, and the Motor Neuron Disease Association UK.
Weakness of the breathing muscles is a common feature of ALS, causing poor quality of life, breathlessness, recurrent chest infections, and eventually death. The most effective treatment currently for ALS-related breathing issues is a non-invasive ventilator (NIV) that people with ALS use to support their breathing. However NIV can be difficult for individuals to use, and even in those who use NIV, muscle weakness progresses and eventually NIV cannot compensate. There is therefore a need for additional and alternative options for treating breathing problems in ALS. Diaphragmatic pacing (DP) offers such a possibility. A pivotal study in the US demonstrated a survival advantage in people with ALS using DP. The FDA approved DP on humanitarian grounds. The pivotal study compared survival of people with ALS using pacing with historical data rather than having a contemporaneous control group. The results from subsequent UK and French studies demonstrated harm in the groups receiving DP compared to contemporaneous control people with ALS not receiving DP (people with ALS who received DP had shortened survival). The aim of this project is to assemble a task force to oversee an independent analysis of all the available data on DP in people with ALS to understand the differing results and explore if there are potentially people with ALS who may benefit from DP.
Grantee: ALS – Christopher McDermott, MBChB, FRCP, PhD
Grant type: Research Grant
Award total:
Institution:
Country:
MDA Resource Center: We’re Here For You
Our trained specialists are here to provide one-on-one support for every part of your journey. Send a message below or call us at 1-833-ASK-MDA1 (1-833-275-6321). If you live outside the U.S., we may be able to connect you to muscular dystrophy groups in your area, but MDA programs are only available in the U.S.
Grant - Summer 2018 - SMA – Jacqueline Montes, PT, EdD, NCS
Jacqueline Montes, assistant professor of Rehabilitation and Regenerative Medicine in the Program for Physical Therapy at Columbia University Medical Center in New York, New York, was awarded an MDA clinical trial travel grant totaling $60,000 to help support the costs of patients traveling to participate in a trial to study oxidative capacity and exercise tolerance in ambulatory SMA.
In a previous study, Dr. Montes’ team found that exercise does not improve function or fitness in ambulatory SMA children and adults despite increases in exercise ability. Understanding the underlying mechanisms preventing the expected improvements is necessary to design appropriate treatment strategies for SMA patients to benefit from exercise.
There has been laboratory evidence to suggest that mitochondria are affected by lack of SMN. A reduction in oxidative capacity disproportionate to lean mass and disease severity would further support evidence of mitochondrial depletion in SMA. Alternative exercise training strategies and/or concomitant targeted therapeutic intervention may be necessary to achieve an aerobic conditioning effect.
The results from this 6-month observational study of 42 patients (14 ambulatory SMA, 14 ambulatory mitochondrial myopathy, and 14 healthy controls) would provide preliminary data, using non-invasive methods, on oxidative capacity in ambulatory SMA patients and disease controls to aid in the design of exercise intervention studies. Furthermore, this information would link previous laboratory and preclinical findings of mitochondrial depletion in SMA to the clinical condition and provide important information for future studies designed to improve oxidative capacity and fitness in SMA patients.
https://doi.org/10.55762/pc.gr.80672
Grantee: SMA – Jacqueline Montes, PT, EdD, NCS
Grant type:
Award total:
Institution:
Country:
